1-(1-Boc-4-Piperidinyl)-4-Iodopyrazole CAS 877399-73-0 Purity ≥99.0% (HPLC)
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer of 1-(1-Boc-4-Piperidinyl)-4-Iodopyrazole (CAS: 877399-73-0) with high quality, intermediate of Crizotinib (CAS: 877399-52-5). Ruifu Chemical can provide worldwide delivery, competitive price, excellent service, small and bulk quantities available. Purchase Crizotinib Intermediates, Please contact: alvin@ruifuchem.com
| Chemical Name | 1-(1-Boc-4-Piperidinyl)-4-Iodopyrazole |
| Synonyms | 1-Boc-4-(4-Iodo-1H-Pyrazol-1-yl)piperidine; tert-Butyl 4-(4-Iodo-1H-Pyrazol-1-yl)piperidine-1-Carboxylate; tert-Butyl 4-(4-Iodopyrazolyl)piperidinecarboxylate; Crizotinib Impurity 16 |
| Stock Status | In Stock, Commercial Production |
| CAS Number | 877399-73-0 |
| Molecular Formula | C13H20IN3O2 |
| Molecular Weight | 377.22 g/mol |
| Melting Point | 97℃ |
| Density | 1.60±0.10 g/cm3 |
| Sensitive | Light Sensitive |
| Storage Temp. | 2~8℃, Protect From Light |
| COA & MSDS | Available |
| Origin | Shanghai, China |
| Category | Intermediate of Crizotinib (CAS: 877399-52-5) |
| Brand | Ruifu Chemical |
| Items | Inspection Standards | Results |
| Appearance | White to Light Yellow Solid | White Solid |
| Purity / Analysis Method | ≥99.0% (HPLC) | 99.58% |
| Infrared Spectrum | Conforms to Structure | Complies |
| 1 H NMR Spectrum | Conforms to Structure | Complies |
| ESI+ | Conforms | Complies |
| Conclusion | The product has been tested & complies with the given specifications | |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Keep the container tightly closed and store in a cool, dry (2~8℃) and well-ventilated warehouse away from incompatible substances. Protect from light and moisture.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery.
How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.
Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.
Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.
Quality Assurance? Strict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.
Samples? Most products provide free samples for quality evaluation, shipping cost should be paid by customers.
Factory Audit? Factory audit welcome. Please make an appointment in advance.
MOQ? No MOQ. Small order is acceptable.
Delivery Time? If within stock, three days delivery guaranteed.
Transportation? By Express (FedEx, DHL), by Air, by Sea.
Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.
Custom Synthesis? Can provide custom synthesis services to best fit your research needs.
Payment Terms? Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
1-(1-Boc-4-Piperidinyl)-4-Iodopyrazole (CAS: 877399-73-0) with high quality, intermediate of Crizotinib (CAS: 877399-52-5). Crizotinib is a targeted therapy drug for non-small cell lung cancer developed by Pfizer, USA, secorri is a frontier and epoch-making drug in the field of targeted therapy for lung cancer. It was approved for marketing in the United States in August 2011 and was written into international lung cancer treatment guidelines at the end of the year as a first-line drug for ALK-positive patients. Co-approved with Crizotinib is the first genetic diagnosis method using fluorescence in situ hybridization (FISH)-VSIs ALK Break Apart FISH Probe Kit, this is the method currently used in global clinical trials to detect EML4-ALK fusion genes in NSCLC. This test will help identify patients who may benefit from Crizotinib treatment. on 25, this is the first drug to be used in the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as determined by an SFDA-approved assay.
Crizotinib (PF-02341066) Crizotinib is a potent c-Met and ALK inhibitor, the IC50 values in the cell assay were 11 nM and 24 nM, respectively. It is also a potent inhibitor of ROS1 with a Ki value of less than 0.025 nM. Crizotinib can induce autophagy in a variety of lung cancer cell lines by inhibiting the STAT3 pathway.
